As afatinib is a substrate for the P-glycoprotein ( P-gp ) pump transporter the three studies presented here investigated the pharmacokinetics of afatinib in the presence of a potent inhibitor ( ritonavir ) or inducer -LSB- rifampicin ( rifampin ) -RSB- of P-gp .